177 related articles for article (PubMed ID: 34596344)
1. Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma.
Zhang H; Shan G; Cai B; Bi G; Chen Z; Liang J; Besskaya V; Zheng Y; Guo W; Wang L; Xu S; Zhan C
Thorac Cancer; 2021 Nov; 12(22):3011-3018. PubMed ID: 34596344
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
Matsuura Y; Ninomiya H; Ichinose J; Nakao M; Okumura S; Nishio M; Mun M
J Thorac Cardiovasc Surg; 2022 Feb; 163(2):441-451.e1. PubMed ID: 33131892
[TBL] [Abstract][Full Text] [Related]
3. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
[TBL] [Abstract][Full Text] [Related]
4. Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database.
Matsuura Y; Mun M; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H;
J Surg Oncol; 2023 Oct; 128(5):916-924. PubMed ID: 37403534
[TBL] [Abstract][Full Text] [Related]
5. Resected stage I anaplastic lymphoma kinase-positive lung adenocarcinoma has a negative impact on recurrence-free survival.
Fujibayashi Y; Tane S; Kitazume M; Kuroda S; Kimura K; Kitamura Y; Nishio W
Thorac Cancer; 2022 Apr; 13(8):1109-1116. PubMed ID: 35274461
[TBL] [Abstract][Full Text] [Related]
6. Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas.
Wang H; Wang Y; Zhang H; Han Y; Li Q; Ye Z
Clin Radiol; 2020 Jul; 75(7):562.e21-562.e29. PubMed ID: 32307109
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase fusion protein expression is associated with a favorable prognosis in resected invasive mucinous lung adenocarcinoma: A retrospective study from two Chinese tertiary hospitals.
Wang J; Wei P; Liu J; Su P; Xing A; Jing H; Hao J
J Cancer Res Ther; 2022 Apr; 18(2):445-451. PubMed ID: 35645113
[TBL] [Abstract][Full Text] [Related]
9. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.
Woo JH; Kim TJ; Kim TS; Han J
Sci Rep; 2020 Oct; 10(1):16251. PubMed ID: 33005033
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
[TBL] [Abstract][Full Text] [Related]
12. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma.
Liu Y; Ye X; Yu Y; Lu S
J Thorac Dis; 2019 Oct; 11(10):4258-4270. PubMed ID: 31737311
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma.
He W; Xu D; Wang Z; Wu H; Xiang X; Tang B; Jiang W; Cui Y; Wang H; Jiang N; Sun Y; Chen Y; Li S; Hou M; Zhang Y; Wang L; Ke ZF
J Transl Med; 2019 Jan; 17(1):32. PubMed ID: 30658713
[TBL] [Abstract][Full Text] [Related]
15. Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.
Tao H; Cai Y; Shi L; Tang J; Liu Z; Wang Z; Bai L; Liu Z
Thorac Cancer; 2017 Jan; 8(1):8-15. PubMed ID: 27779369
[TBL] [Abstract][Full Text] [Related]
16. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.
Fan J; Wu J; Huang B; Zhu Y; Shi H; Dai X; Nie X
Diagn Pathol; 2020 May; 15(1):42. PubMed ID: 32375829
[TBL] [Abstract][Full Text] [Related]
17. Individualized nomogram for predicting ALK rearrangement status in lung adenocarcinoma patients.
Song L; Zhu Z; Wu H; Han W; Cheng X; Li J; Du H; Lei J; Sui X; Song W; Jin ZY
Eur Radiol; 2021 Apr; 31(4):2034-2047. PubMed ID: 33146791
[TBL] [Abstract][Full Text] [Related]
18. Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Song P; Zhang X; Yang D; Wang H; Si X; Zhang L
Thorac Cancer; 2020 May; 11(5):1216-1223. PubMed ID: 32181989
[TBL] [Abstract][Full Text] [Related]
19. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
[TBL] [Abstract][Full Text] [Related]
20. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
